Mylan Launches Another Generic - Analyst Blog

By
A A A

Mylan Inc. ( MYL ) recently announced that it has launched its generic version of Pfizer's ( PFE ) Dilantin Chewable Tablets (phenytoin - 50 mg). The company started shipping the product following the receipt of final US Food and Drug Administration (FDA) approval.

Dilantin is approved for controlling generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. It is also indicated for the prevention and treatment of seizures at the time of or after neurosurgery. According to IMS Health, phenytoin generated US revenues of approximately $16.5 million for the 12 months ending September 30, 2012.

Mylan had 185 ANDAs pending FDA clearance, targeting $80.6 billion in sales annually. Mylan believes that about 35 of these pending abbreviated new drug applications (ANDAs) are first-to-file opportunities, representing $21.2 billion in branded sales. The revenue figures are as per IMS Health for the 12 months ending June 30, 2012.

Our Recommendation

Mylan's geographic reach and product depth along with a robust generic product pipeline are contributing to the company's overall growth. However, we remain cautious of the company's performance in the Europe, Middle East and Africa (EMEA) region.

Additionally, as most of the large branded drugs are due to lose patent exclusivity within the 2017-2018 period, we have little visibility on the growth prospects of generic companies like Mylan beyond that timeframe.

In view of these challenges, we see limited upside from current levels and maintain a Neutral recommendation on Mylan. The stock carries a Zacks #3 Rank (Hold) in the short run.

Currently, pharma companies like Valeant Pharmaceuticals Internat ( VRX ), carry a Zacks #1 Rank (Strong Buy).



MYLAN INC (MYL): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

VALEANT PHARMA (VRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: MYL , PFE , VRX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Quick on Your Feet
Quick on Your Feet                  
Early Entrepreneurship
Early Entrepreneurship              

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com